KYMR Kymera Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Clinical-stage biopharma specializing in targeted protein degradation (TPD) oral small molecules for immunology and serious diseases
• • New products: Initiated Phase 2b trials for KT-621 (oral STAT6 degrader) in atopic dermatitis and asthma; Phase 1 trial started for KT-579 (oral IRF5 degrader)
• • Strategic shifts: Expanded collaborations with Sanofi for IRAK4 degrader advancing to clinical testing in 2026 and new agreement with Gilead for molecular glue degraders targeting CDK2
• • Quantitative highlight: KT-621 Phase 1b trial showed 98% median STAT6 degradation in blood, 62-74% reduction in Type 2 biomarkers, and up to 63% improvement in EASI scores by Day 29
• • Noteworthy fact: First demonstration of IL-31 and FeNO reductions in AD patients with oral STAT6 degradation therapy, potentially matching injectable biologics' efficacy

Risk Factors

• • Regulatory risk: FDA approval timing and success uncertainty for STAT6, IRF5, and IRAK4 programs affecting clinical development and commercialization
• • Macroeconomic risk: Potential capital exhaustion before 2029 despite $1.62B cash, risking delays in R&D and clinical trials
• • Operational risk: Dependency on third-party manufacturers and CROs for supply of clinical trial materials and manufacturing
• • Competitive risk: Collaboration with Sanofi and Gilead required to advance programs, risk if partners prioritize other pipeline assets
• • Financial risk: Net losses of $311.4M in 2025 with accumulated deficit $1.07B, requiring substantial future financings to sustain operations

Management Discussion & Analysis

• • No revenue or profitability figures disclosed in MD&A section
• • No segment performance or cash flow details provided
• • No capital allocation information (buybacks, dividends, capex) included
• • No forward-looking guidance or management outlook mentioned

What are the latest KYMR SEC filings in 2026?

Kymera Therapeutics, Inc. (KYMR) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did KYMR file its most recent 10-K annual report?

Kymera Therapeutics, Inc. (KYMR) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view KYMR 10-Q quarterly reports?

Kymera Therapeutics, Inc. (KYMR)'s most recent 10-Q quarterly report was filed on April 30, 2026. SignalX displays every KYMR 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has KYMR filed recently?

Kymera Therapeutics, Inc. (KYMR)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find KYMR insider trading activity (Form 4)?

SignalX aggregates every KYMR Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does KYMR file with the SEC?

Kymera Therapeutics, Inc. (KYMR) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new KYMR filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Kymera Therapeutics, Inc. (KYMR).

What is KYMR's SEC CIK number?

Kymera Therapeutics, Inc. (KYMR)'s SEC CIK (Central Index Key) number is 1815442. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1815442 to look up all KYMR filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find KYMR return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Kymera Therapeutics, Inc. (KYMR) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.